KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02162 KEYMED BIO-B

Market Closed 07-24 16:08:05

82.800

-2.700

-3.16%

High86.800	Low81.650	Vol1.74M
Open84.900	D1 Closing85.500	Amplitude6.02%
Mkt Cap24.76B	Tradable Cap24.76B	Total Shares299.00M
T/O145.37M	T/O Rate0.58%	Tradable Shares299.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":82.8,"timestamp":1784880485003,"preClose":85.5,"halted":0,"volume":1741010,"delay":0,"changeRate":-0.03157894736842109,"floatShares":299000000,"shares":299000000,"eps":-2.2092856582703346,"marketStatus":"Market Closed","change":-2.7,"latestTime":"07-24 16:08:05","open":84.9,"high":86.8,"low":81.65,"amount":145374921,"amplitude":0.060234,"askPrice":82.85,"askSize":38000,"bidPrice":82.75,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.240516397942219,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":85.5,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.7171027403175427,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162/wiki","defaultTab":"wiki","newsList":[{"id":"2653874800","title":"Hong Kong Stocks Rise on Thursday; Tsaker New Energy Soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2653874800","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653874800?lang=en_us&edition=fundamental","pubTime":"2026-07-23 17:15","pubTimestamp":1784798150,"startTime":"0","endTime":"0","summary":"Hong Kong stocks closed higher on Thursday as investors looked ahead to next week's U.S. Federal Reserve meeting and welcomed a new agreement between Malaysian and Hong Kong regulators to strengthen c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1587","02833","MHImain","03115","01986","MCHmain","83115","BK1129","02800","BK1583","09115","07200","BK1574","03037","HSTECH","82800","03419","07300","HHImain","HSI","BK1161","02162","513600","07500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171394971","title":"Keymed Bio-B Shares Surge Over 3% Following Inclusion of CM512 in China's Breakthrough Therapy Designation List","url":"https://stock-news.laohu8.com/highlight/detail?id=1171394971","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171394971?lang=en_us&edition=fundamental","pubTime":"2026-07-23 14:25","pubTimestamp":1784787923,"startTime":"0","endTime":"0","summary":"Shares of Keymed Bio-B (02162) have risen more than 3%. At the time of writing, the stock is up 2.03%, trading at HK$85.3 with a turnover of HK$85.1319 million.The upward movement follows a company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4585","02162","KCAI","BK1587","BK1161","BK4588","VXUS","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184064929","title":"KEYMED BIO-B's CM512 Designated as Breakthrough Therapy for Chronic Rhinosinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=1184064929","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184064929?lang=en_us&edition=fundamental","pubTime":"2026-07-23 12:04","pubTimestamp":1784779464,"startTime":"0","endTime":"0","summary":"An announcement has been made by KEYMED BIO-B (ASX: 02162) regarding its key research and development product, CM512 (TSLP/IL-13 bispecific antibody).The product has been included in the Breakthrough...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1587","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653132457","title":"Keymed Biosciences Advances Phase II Trials for CM512 Across Multiple Respiratory and Inflammatory Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2653132457","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653132457?lang=en_us&edition=fundamental","pubTime":"2026-07-23 12:01","pubTimestamp":1784779262,"startTime":"0","endTime":"0","summary":"Keymed Biosciences advances Phase II trials for CM512 across multiple respiratory and inflammatory indicationsKeymed’s CM512 was added to China’s Breakthrough Therapy Designation list, setting up acce","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL52PGqK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02162","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653132107","title":"Keymed Biosciences Says China Regulator Grants Breakthrough Therapy Designation for CM512 in Crswnp","url":"https://stock-news.laohu8.com/highlight/detail?id=2653132107","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653132107?lang=en_us&edition=fundamental","pubTime":"2026-07-23 12:00","pubTimestamp":1784779258,"startTime":"0","endTime":"0","summary":"Keymed Biosciences says China regulator grants breakthrough therapy designation for CM512 in CRSwNPKeymed Biosciences’ CM512 was added to China’s NMPA CDE breakthrough therapy list for chronic rhinosi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL5prN0P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keymed Biosciences Says China Regulator Grants Breakthrough Therapy Designation for CM512 in Crswnp","news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1574","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653713269","title":"Keymed Biosciences - Cm512 Included in Breakthrough Therapy Designation List for Chronic Rhinosinusitis with Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2653713269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653713269?lang=en_us&edition=fundamental","pubTime":"2026-07-23 12:00","pubTimestamp":1784779236,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43O1CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","BK1574","02162","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185053835","title":"HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185053835","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185053835?lang=en_us&edition=fundamental","pubTime":"2026-07-20 11:36","pubTimestamp":1784518575,"startTime":"0","endTime":"0","summary":"Monday, July 20, Hong Kong biomedical shares staged a broad rally. $REMEGEN(09995)$, $WUXI XDC(02268)$ and $KEYMED BIO-B(02162)$ climbed more than 8%, while $JUNSHI BIO(01877)$ gained over 7% and $AKESO(09926)$ advanced above 6%. $WUXI BIO(02269)$ edged up nearly 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","02162","01877","09926","02268","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175845079","title":"Movement Alert｜Keymed Biosciences Rises 7.1% in Regular Trading, Profit Alert and Sector-Wide Institutional Buying Boost Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1175845079","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175845079?lang=en_us&edition=fundamental","pubTime":"2026-07-20 10:35","pubTimestamp":1784514953,"startTime":"0","endTime":"0","summary":"On July 20, Keymed Biosciences (02162.HK) rose 7.1% in regular trading, trading at HK$87.9/share, with turnover of HK$53.46 million.On the news front, the innovative drug sector saw broad-based...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152900130","title":"Movement Alert｜Keymed Biosciences Drops 5.12% in Regular Trading, Biotech Sector Broadly Weakens After Prior Catalysts Priced In","url":"https://stock-news.laohu8.com/highlight/detail?id=1152900130","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152900130?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:22","pubTimestamp":1784254951,"startTime":"0","endTime":"0","summary":"On July 17, Keymed Biosciences (02162.HK) fell 5.12% in regular trading, trading at HK$82.15/share, with turnover of HK$65.53 million.The decline came amid a broad sell-off across the biotech sector,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651646415","title":"Keymed Biosciences Inc. (HKG:2162) About To Shift From Loss To Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2651646415","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651646415?lang=en_us&edition=fundamental","pubTime":"2026-07-16 10:36","pubTimestamp":1784169405,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Keymed Biosciences...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-hkg2162-about-to-shift-from-loss-to-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-inc-hkg2162-about-to-shift-from-loss-to-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","BK1574","BK1587","BK1161","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651611754","title":"Keymed Biosciences Expects H1 Profit at Least RMB 1.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651611754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651611754?lang=en_us&edition=fundamental","pubTime":"2026-07-15 22:37","pubTimestamp":1784126273,"startTime":"0","endTime":"0","summary":"Keymed Biosciences expects H1 profit at least RMB 1.2 billionKeymed guided for H1 2026 profit of at least RMB 1.2 billion, versus a loss of about RMB 79 million a year earlier.Turnaround driven by oth","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDLbZLtsN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1587","BK1161","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106970378","title":"KEYMED BIO-B Shares Surge Over 9% Intraday as Dual-Antibody Drug CM512 Designated for Breakthrough Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1106970378","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106970378?lang=en_us&edition=fundamental","pubTime":"2026-07-15 15:36","pubTimestamp":1784100984,"startTime":"0","endTime":"0","summary":"Shares of KEYMED BIO-B (02162) surged more than 9% during the trading session. At the time of writing, the stock was up 6.69% to HK$86.15, with a turnover of HK$468 million.The upward movement...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","KCAI","02162","BK4588","BK1583","BK1587","VXUS","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177680001","title":"Movement Alert｜Keymed Biosciences Rises 5.08% in Regular Trading, Core Product Included in New National Essential Drug List with Multiple Brokerages Maintaining Buy Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1177680001","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177680001?lang=en_us&edition=fundamental","pubTime":"2026-07-15 09:50","pubTimestamp":1784080219,"startTime":"0","endTime":"0","summary":"On July 15, Keymed Biosciences (02162.HK) rose 5.08% in regular trading, trading at 85.45 HKD/share, with turnover of approximately 74.15 million HKD.The rally was driven by dual catalysts: the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114859510","title":"GTHT Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1114859510","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114859510?lang=en_us&edition=fundamental","pubTime":"2026-07-09 14:31","pubTimestamp":1783578688,"startTime":"0","endTime":"0","summary":"GTHT Securities has released a research report initiating coverage on KEYMED BIO-B (02162). The firm has assigned a Buy rating to the company's shares.The valuation was conducted using a Discounted...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02162","BK1147","BK1161","02611","BK1564","BK1574","BK1583","161027","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189139838","title":"Guotai Haitong Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1189139838","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189139838?lang=en_us&edition=fundamental","pubTime":"2026-07-09 09:42","pubTimestamp":1783561367,"startTime":"0","endTime":"0","summary":"Guotai Haitong Securities has issued a research report initiating coverage on KEYMED BIO-B (02162), assigning a Buy rating and a target price of HK$138.91. The valuation, derived using a Discounted...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02611","BK1161","BK1564","BK1147","161027","BK1574","EWH","BK1587","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131894691","title":"Innovative Drug Sector Maintains Upward Momentum on Favorable Regulatory Developments and Accelerating Internationalization","url":"https://stock-news.laohu8.com/highlight/detail?id=1131894691","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131894691?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:10","pubTimestamp":1783303836,"startTime":"0","endTime":"0","summary":"The innovative drug concept continued its upward trend in Hong Kong trading.Innocare (09969) rose 7.95% to HK$14.12, SBP GROUP (01177) gained 7.38% to HK$5.09, and KEYMED BIO-B (02162) advanced 7.01%...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0880133367.SGD","IBBQ","LU1226288170.HKD","01801","BK1589","BK1191","09969","LU1807302812.USD","02162","LU0326950275.SGD","IE00B5MMRT66.SGD","BK1161","LU0072913022.USD","LU2242644610.SGD","LU1328277881.USD","LU2097828557.USD","BK1521","LU1152091754.HKD","LU2328871848.SGD","BK4588","06978","IE00BZ08YS42.EUR","IE0008369823.USD","LU1008478684.HKD","01177","IE00B031HY20.USD","LU1993786604.SGD","BK1583","KCAI","LU2488822045.USD","VXUS","IE00BZ08YR35.GBP","LU0502904849.HKD","HK0000165453.HKD","LU0315179316.USD","LU0501845795.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","BK1574","LU0455707207.USD","LU0140636845.USD","LU1226287875.USD","LU1226287792.SGD","159992","LU2097828714.EUR","LU2039709279.SGD","BK1587","LU2097828474.EUR","IE00B543WZ88.USD","KURE","LU1152091168.USD","LU1226287529.USD","01093","LU1226288253.USD","MEDX","LU1951186391.HKD","LU1960683339.HKD","BK4585","BK1515","IE0008368742.USD","SG9999004220.SGD","LU2097828631.EUR","LU0067412154.USD","LU1969619763.USD","LU2097828805.USD","LU1813983027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149233574","title":"Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149233574","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149233574?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:58","pubTimestamp":1783303082,"startTime":"0","endTime":"0","summary":"Hong Kong innovative drug stocks jumped in market trading. $HAIXI PHARMA(02637)$, $INNOCARE(09969)$ up 7%; $KEYMED BIO-B(02162)$ up 5%; $REMEGEN(09995)$, $INNOVENT BIO(01801)$, $SIMCERE PHARMA(02096)$ up 4%; $LEPU BIO(02157)$ up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02637","02162","SOXL","01801","09969","02096","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172971835","title":"Movement Alert｜Keymed Biosciences Rises 5.16% in Regular Trading, Dual Insurance Directory Policy and Two New Drug Clinical Approvals Fuel Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1172971835","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172971835?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:46","pubTimestamp":1783302389,"startTime":"0","endTime":"0","summary":"On July 6, Keymed Biosciences rose 5.16% in regular trading, trading at 85.0 HKD/share, with turnover of approximately 115 million HKD, extending its recent strong momentum.On the news front,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185134067","title":"Movement Alert｜Keymed Biosciences Rises 5.34% in Regular Trading, Dual Insurance Directory Policy and Long-Acting AD Track Valuation Reshaping Drive Continued Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1185134067","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185134067?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:42","pubTimestamp":1783042962,"startTime":"0","endTime":"0","summary":"On July 3, Keymed Biosciences rose 5.34% in regular trading, trading at HK$78.15 per share, with turnover of HK$60.27 million. The biotech sector broadly strengthened, continuing momentum from the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181816324","title":"Movement Alert｜Keymed Biosciences Rises 9.4% in Regular Trading, Dual Medical Insurance Directory Policy Catalyzes Long-Acting AD Track Revaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1181816324","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181816324?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:17","pubTimestamp":1782958659,"startTime":"0","endTime":"0","summary":"On July 2, Keymed Biosciences (02162.HK) rose 9.4% in regular trading, trading at HK$77.1/share, with turnover of HK$203 million. The broader biotech sector strengthened simultaneously.On the news...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.3574},{"period":"3month","weight":0.0895},{"period":"6month","weight":0.4539},{"period":"1year","weight":0.3431},{"period":"ytd","weight":0.5491}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.139787},{"month":8,"riseRate":0.6,"avgChangeRate":0.038036},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"KEYMED BIO-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KEYMED BIO-B,02162,KEYMED BIO-B股票,KEYMED BIO-B股票老虎,KEYMED BIO-B股票老虎国际,KEYMED BIO-B行情,KEYMED BIO-B股票行情,KEYMED BIO-B股价,KEYMED BIO-B股市,KEYMED BIO-B股票价格,KEYMED BIO-B股票交易,KEYMED BIO-B股票购买,KEYMED BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}